hengrui glp-1 China Challenges Leaders, ㅤ, Kailera licensed a portfolio of obesity therapies from China's Jiangsu Hengrui, including a Phase 3 GLP-1 candidate that delivered up to 10.9% average weight loss at Hengrui Pharma and Kailera Therapeutics

Name: hengrui glp-1 China Challenges Leaders, ㅤ, Kailera licensed a portfolio of obesity therapies from China's Jiangsu Hengrui, including a Phase 3 GLP-1 candidate that delivered up to 10.9% average weight loss at Hengrui Pharma and Kailera Therapeutics
Brand: skorenge.com
SKU: 76559495310
Price: 23.31 USD
Availability: InStock
Rating: 4.6822 (23 reviews)

SKU: 76559495310

4.7

USD23.31 USD50.31

Pay in 4 interest-free payments of $5.83 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 31 - Aug 5

Live Spec

Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP 1 GIP Receptor Agonist HRS9531 Tue, 07 15 2025 08:00 Kailera, Hengrui to advance oral obesity drug into 2 new trials Hengrui has submitted an IND application for HRS5931 in China New GLP 1R agonists disclosed in Youngene Therapeutics patent BioWorld Hengrui, Kailera's GLP 1 pill posts encouraging efficacy but high side effect rates in late stage China trials

Store: skorenge.com · Domain: skorenge.com

Description

Developed specifically to act as a pillar of support during phases of reduced food intake, this supplement actively serves to meet the body's micronutrient needs